Post-exercise Glucose Management in Type 1 Diabetes: Comparing Carbohydrate Intake and Insulin Reduction Strategies.

Endocr PractApr 9, 2026 (epub)
Clinical ResearchEndocrinology

Sémah Tagougui, Elsa Heyman, Nadine Taleb et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized comparative study evaluated two post-exercise glucose management strategies in 46 adults and adolescents with type 1 diabetes using continuous subcutaneous insulin infusion. After a 60-minute cycling session, participants received either reduced basal and dinner bolus insulin or a carbohydrate-snack strategy. Over 13 hours of recovery, the strategies did not differ significantly in time within the target glucose range or time below range. However, the first hypoglycemic event occurred later with basal insulin reduction: 140 vs 83 min (P= .04).

Key findings

  • Time within 4.0-10.0 mmol/l was 54.4 ± 26.2 vs 57.7 ± 25.9% for the two strategies, with no significant difference.
  • Time below 4.0 mmol/l was 1.8 ± 5.9 vs 5.5 ± 9.2%, a difference that did not reach statistical significance.
  • Time to first interstitial glucose <4.0 mmol/L was longer with basal insulin reduction: 140 vs 83 min (P= .04).

Why it matters

Post-exercise hypoglycemia is a relevant concern in type 1 diabetes, and this comparison suggests that glucose stability over the recovery period may be similar with either approach while the timing of the first low glucose event differs. The findings help characterize a potential trade-off between insulin adjustment and carbohydrate-based strategies after exercise.

What to keep in mind

The study reports substantial interindividual variability, reflected in large standard deviations; the reported comparison covers only the 13-hour recovery period after a specific exercise session.

Source

Published in Endocr Pract. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.